TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01101061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT02591862

Intervention type: DRUG
Group type: OTHER
Intervention: Coversin
Description: Patients enrolled in this protocol will initially be treated with an ablating dose of Coversin and daily repeat maintenance doses calculated according to body weight, the ablating dose to be 0.57mg/kg. Thereafter the daily repeat dose will be titrated according to clinical response and complement inhibition determined by CH50 ELISA. The initial repeat dose will be 25% of the ablating dose and this will be adjusted up or down if necessary once steady state is reached (5 days).
Study: NCT02931578

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose100

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose50

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose42

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: For each OGTT, subjects will consume 50g of sweetener dissolved in water at a comfortable pace within 10 minutes. Blood samples for plasma glucose and insulin will be taken at -20, 0, 15, 30, 45, 60, 90 and 120 min after consuming the glucose drink. Plasma fructose will be tested at baseline, 30, 60, 90 and 120 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: For each OGTT, subjects will consume 50g of sweetener dissolved in water at a comfortable pace within 10 minutes. Blood samples for plasma glucose and insulin will be taken at -20, 0, 15, 30, 45, 60, 90 and 120 min after consuming the glucose drink. Plasma fructose will be tested at baseline, 30, 60, 90 and 120 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: For each OGTT, subjects will consume 50g of sweetener dissolved in water at a comfortable pace within 10 minutes. Blood samples for plasma glucose and insulin will be taken at -20, 0, 15, 30, 45, 60, 90 and 120 min after consuming the glucose drink. Plasma fructose will be tested at baseline, 30, 60, 90 and 120 minutes.
Study: NCT04419363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Burosumab Injection
Description: Children affected with X-linked hypophosphatemia were switched from conventional therapy to burosumab
Study: NCT02868372

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone iodine
Description: After closure of the anterior wall of the rectus sheath, the subcutaneous tissues of the cesarean section wound will be swabbed with 10% undiluted Povidone iodine without mobbing.
Study: NCT02023749

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nut group
Study: NCT05174598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol/AKVANO, 50 μg/g cutaneous solution
Description: Topical spray formulation containing Calcipotriol 50 μg/g. Twice daily treatment by spraying on a psoriasis affected area for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol Ointment 50 micrograms/g
Description: Topical Ointment formulation containing Calcipotriol 50 micrograms/g. Twice daily treatment by applying on a psoriasis affected area for 8 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical spray formulation containing Vehicle of test formulation. Twice daily treatment by spraying on a psoriasis affected area for 8 weeks.
Study: NCT00770588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Dose form: 250 mg/tablet; Route: oral; Frequency: 1 tablet per day; Duration: until to objective PD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To match Gefitinib
Study: NCT00543153

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview lasting approximately 30-45 minutes.
Study: NCT03716765

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: locally injected vitamin D
Description: locally injected vitamin d as non surgical method for periodontal regeneration of vertical bony defects

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: locally injected vitamin D
Description: locally injected vitamin d as non surgical method for periodontal regeneration of vertical bony defects
Study: NCT01137747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Study: NCT01426113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost ophthalmic solution formulation A
Description: 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol ophthalmic solution
Description: 1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost vehicle
Description: 1 drop of bimatoprost vehicle in the affected eye(s) in the morning for 6 weeks, followed by 1 drop of bimatoprost vehicle in the affected eye(s) in the evening for 6 weeks.
Study: NCT00728299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PomWonderful Juice
Description: 8 oz per day each day for 78 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo juice
Description: 8 oz per day for 78 weeks
Study: NCT00002668

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Observation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention and Behavioral Skills Training
Study: NCT04539067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HHMG
Description: Induction of ovulation from the 2nd day of cycle to 5th day then follow the diameter of follicle Use transvaginal ultrasound When diameter of follicle 18 to 22 patients receiving HMG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HHMG
Description: Induction of ovulation from the 2nd day of cycle to 5th day then follow the diameter of follicle Use transvaginal ultrasound When diameter of follicle 18 to 22 patients receiving HMG
Study: NCT02219399

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 600 mg DHA
Description: Pregnant women were given 600 mg DHA in the last trimester of pregnancy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 300 mg DHA
Description: Pregnant women were given 300 mg DHA in the last trimester of pregnancy and through the first 3 months of breastfeeding

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pregnant women in the control group received placebo of either olive oil or high oleic acid sunflower oil during the study period
Study: NCT02276534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SENSE Theatre
Description: A peer-mediated, theatre-based intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Intervention
Study: NCT03336099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa Treatment
Description: * Bath with immersion shower~* Overall shower, penetrating shower~* Multiple local application cataplasm~* Single local application cataplasm~* Inhalation or collective steam bath~* Individual physiotherapy technique
Study: NCT02315768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Study: NCT02429986

Intervention type: DEVICE
Group type: OTHER
Intervention: Adaptive Servo-Ventilation
Description: Adaptive Servo-Ventilation proceeds by continually measuring either minute ventilation or airflow and calculates a target ventilation to be applied as needed.
Study: NCT02353416

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Glycemic Index Mediterranean Diet
Description: Prescription of a Low Glycemic Index (less than 50) Mediterranean Diet with no more than 10% of total daily calories coming from saturated fats, high in monounsaturated fatty acids (MUFA) from olive oil and omega-3 polyunsaturated fatty acids (ω3PUFA), from both plant and marine sources

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: INRAM Guidelines' diet
Description: Prescription of INRAM guidelines' diet
Study: NCT00732992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib, Pemetrexed
Description: Sunitinib daily by oral capsule in a continuous daily dosing regimen with pemetrexed every 3 weeks until progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib, Pemetrexed
Description: Sunitinib daily by oral capsule administered for 2 weeks out of every 3 weeks with pemetrexed every 3 weeks until progression or unacceptable toxicity.
Study: NCT02944396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: intravenous; administered on Day 1 via infusion in a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: intravenous; administered on Day 1 via infusion in a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: intravenous; administered on Day 1 via infusion in a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: intravenous; administered on Day 1 via infusion in a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: intravenous; administered on Day 1 via infusion in a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: oral capsule; varying doses administered on Days -2 to 5 in a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: oral capsule; varying doses administered on Days -2 to 5 in a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: intravenous; administered on Day 1 via infusion in a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: intravenous; administered on Day 1 via infusion in a 21-day cycle
Study: NCT00728000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 IV on day 1 and day 15 over 30mins.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 100mg/m2 IV on days 1 and 15 given over 120 mins.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 100mg/day PO on days 1-14 and 15-28
Study: NCT04751136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cerebrolysin
Description: Infants of the treatment group were given Cerebrolysin in a dose of 0.1 ml / kg body weight once weekly intramuscular injection for 12 month (total of 48 injections).Each selected infant, in both treatment and control group, was assessed as regard: Socioeconomic status, Nutritional status and feeding practice, assessed for neurocognitive development
Study: NCT01287728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment BY METROMIDAZOLE
Description: Abnormal vaginal flora (a Nugent score of 4-10 or 3 Amsel criteria) will be treated with 2g of oral metronidazole
Study: NCT04120142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation+IMT
Description: The experimental group receives inspiratory muscle training and aerobic exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: The Active Comparator group received only aerobic exercise.
Study: NCT00377988

Intervention type: DRUG
Intervention: Transdermal Contraceptive System
Description: In each 4-week period, exposed subjects will wear a transdermal patch containing 6 mg norelgestromin and 0.75 mg EE worn for each of 3 consecutive weeks with no patch the 4th week.

Intervention type: DRUG
Intervention: Norgestimate-containing oral contraceptives with EE
Description: NGM-OCs with 34 mcg of EE taken during each 4 week period for 21 consecutive days, then no pill or a drug-free pill 7 days.
Study: NCT01210378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin patch
Description: Nitroglycerin patch
Study: NCT03258671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TK Inhibitor
Description: ·EGFR-TKI：gefitinib will be administered 250mg/d ivgtt qd; icotinib will be administered 150mg/d ivgtt tid;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TK Inhibitor
Description: ·EGFR-TKI：gefitinib will be administered 250mg/d ivgtt qd; icotinib will be administered 150mg/d ivgtt tid;

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: High dose group：DTGTV=70Gy；~* first course radiotherapy：40Gy/20f/4w（DTPTV：36Gy/20f/4w）,2Gy/f/d；~* late course radiotherapy：1.5Gy/f、2f/d、interval≥6 hs、DTGTV=30Gy（DTPTV=27Gy）。~Low dose group：DTGTV=50Gy;~* first course radiotherapy：32Gy/16f/3w（DTPTV为28.8Gy/16f/3w），2Gy/f/d；~* late course radiotherapy：1.5Gy/f、2f/d、interval≥6小时、DTGTV为18Gy（DTPTV为16.2Gy）。

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: High dose group：DTGTV=70Gy；~* first course radiotherapy：40Gy/20f/4w（DTPTV：36Gy/20f/4w）,2Gy/f/d；~* late course radiotherapy：1.5Gy/f、2f/d、interval≥6 hs、DTGTV=30Gy（DTPTV=27Gy）。~Low dose group：DTGTV=50Gy;~* first course radiotherapy：32Gy/16f/3w（DTPTV为28.8Gy/16f/3w），2Gy/f/d；~* late course radiotherapy：1.5Gy/f、2f/d、interval≥6小时、DTGTV为18Gy（DTPTV为16.2Gy）。
Study: NCT04368832

Intervention type: OTHER
Intervention: Remote consultation
Description: One or more consultation is conducted by phone or teleconsultation during prenatal monitoring
Study: NCT03994237

Intervention type: OTHER
Intervention: semi-structured interview
Description: The tool used is a nurse card: there is no validated tool on the expectations of the caregiver in his memory referral. This is a pragmatic and practical questionnaire memory consultation request and domestic life with few items, practical use by telephone.
Study: NCT03485703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: the newborn group will receive intravenous azithromycin 10 mg / kg / day once daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the group of newborns will receive 0.9% saline once daily for 5 days
Study: NCT01470144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoprostenol
Description: Administered by continuous intravenous infusion via a central venous catheter; using an ambulatory infusion pump. The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit
Study: NCT02612545

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHA-PPQ)
Description: Co-formulated anti-malarial drug used as standard of care treatment for uncomplicated malaria in Cambodia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PPQ)
Description: Co-formulated anti-malarial drug used as standard of care treatment for uncomplicated malaria in Cambodia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ)
Description: ACT partner drug
Study: NCT02392702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kalydeco
Study: NCT00235248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin
Description: Clopidogrel-aspirin
Study: NCT05194852

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided posterior hydrodilatation
Description: Group I was treated through posterior approach; The injection needle is introduced at the skin surface just lateral to the transducer and in an oblique lateral to medial direction. Group II was treated through anterior rotator interval approach. A 21-gauge needle is introduced into the rotator interval using an oblique path within the imaging plane of the transducer; from lateral to medial, the needle tip is imaged in real time throughout its passage from superficial to deep and is positioned in the biceps tendon sheath between the coracohumeral ligament above and biceps tendon below. Both groups were given the same guided stretching and strengthening exercise program

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided posterior hydrodilatation
Description: Group I was treated through posterior approach; The injection needle is introduced at the skin surface just lateral to the transducer and in an oblique lateral to medial direction. Group II was treated through anterior rotator interval approach. A 21-gauge needle is introduced into the rotator interval using an oblique path within the imaging plane of the transducer; from lateral to medial, the needle tip is imaged in real time throughout its passage from superficial to deep and is positioned in the biceps tendon sheath between the coracohumeral ligament above and biceps tendon below. Both groups were given the same guided stretching and strengthening exercise program

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroid, saline, and local anesthetic
Description: corticosteroid, saline, and local anesthetic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: guided stretching and strengthening exercise program
Description: guided stretching and strengthening exercise program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: guided stretching and strengthening exercise program
Description: guided stretching and strengthening exercise program
Study: NCT03029845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol 1
Description: Participants will take 20 mg propranolol twice a day for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol 2
Description: Participants will take 10 mg propranolol twice a day for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take placebo twice a day for 2 weeks
Study: NCT03301831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resourcefulness Training
Description: Cognitive-behavioral intervention that includes personal and social resourcefulness skills.
Study: NCT03171740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intranasal dexmedetomidine, 1mcg/kg (it is a 100mcg/ml solution)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam oral solution
Description: Oral midazolam, 0.5mg/kg (its a 2mg/ml solution)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral saline
Description: Oral saline, 0.25ml/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasal saline
Description: Nasal saline 0.01ml/kg
Study: NCT02185807

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: video-assisted group
Description: The video assistance patients watch a video in Cantonese or Mandarin explaining the surgery procedure and its risks, benefits and alternatives before discussion with their physicians.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: The control patients receive verbal information and discussion from their physicians.
Study: NCT04509817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture+Usual care
Description: Acupuncture intervention Disposable, sterilized needles (0.25×40 mm and 0.30×50 mm) will be used and selected acupoints will include GV20, CV4, and bilateral BL32, ST25, ST29, EX-CA1, LI4, LR3, SP6, SP9. Subject will be prone position first and BL32 will be inserted with an angle of 30-45° in an inferomedial direction and a depth of 30-50 mm. Once the subject has a needle sensation ('De-qi'), the needle will be removed immediately. Then the subject will be supine position, and GV20, CV4, ST25, ST29, EX-CA1, LI4, LR3, SP6, SP9 will be needled with a depth of 10-40mm. After subject feel 'De-qi', the needles will be placed for 20 min to maintain the stimulation.~Usual care intervention The subjects will receive the health advice including diet with regular meal, enough sleep, and appropriate exercise.~Behavioral: Usual care Usual care intervention The subjects will receive the health advice including diet with regular meal, enough sleep, and appropriate exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care intervention The subjects will receive the health advice
Study: NCT04091204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib tablets
Description: Olaparib is given orally at the dose of 300 mg bid continually as maintenance therapy after a platinum based chemotherapy